HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02696 HENLIUS

Closed 01-22 16:08:18

59.450

-2.400

-3.88%

High62.750	Low58.250	Vol698.40K
Open61.850	D1 Closing61.850	Amplitude7.28%
Mkt Cap32.31B	Tradable Cap9.72B	Total Shares543.49M
T/O41.51M	T/O Rate0.43%	Tradable Shares163.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"HENLIUS","latestPrice":59.45,"timestamp":1769069298005,"preClose":61.85,"halted":0,"volume":698400,"delay":0,"changeRate":-0.03880355699272431,"floatShares":163428541,"shares":543494853,"eps":1.509618,"marketStatus":"Closed","change":-2.4,"latestTime":"01-22 16:08:18","open":61.85,"high":62.75,"low":58.25,"amount":41506454,"amplitude":0.072757,"askPrice":59.45,"askSize":1400,"bidPrice":59,"bidSize":2400,"shortable":3,"etf":0,"ttmEps":1.661924,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769131800000},"marketStatusCode":5,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":61.85,"openAndCloseTimeList":[[1769045400000,1769054400000],[1769058000000,1769068800000]],"volumeRatio":1.397637,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696/tweets","defaultTab":"tweets","newsList":[{"id":"2604199394","title":"Henlius Biotech Receives Chinese Regulatory Nod for Human Trials of HLX701","url":"https://stock-news.laohu8.com/highlight/detail?id=2604199394","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604199394?lang=en_us&edition=fundamental","pubTime":"2026-01-20 17:50","pubTimestamp":1768902603,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech  said it received Chinese regulatory approval to begin human trials of its drug candidate HLX701, according to a Hong Kong bourse filing Tuesday.The firm plans to study the medicine in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000165453.HKD","BK1161","HK0000320223.HKD","BK4588","02696","HK0000320264.USD","LABU","BK4585","HK0000306685.HKD","HK0000306701.USD"],"gpt_icon":0},{"id":"1174517657","title":"HENLIUS (02696): Phase 1b/2 Clinical Trial Application for HLX701 Combined with Cetuximab and Chemotherapy in Advanced Colorectal Cancer Approved by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1174517657","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174517657?lang=en_us&edition=fundamental","pubTime":"2026-01-20 17:09","pubTimestamp":1768900154,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that the Phase 1b/2 clinical trial application (IND) for HLX701 (recombinant human SIRPα-IgG4 Fc fusion protein injection) in combination with cetuximab and chemotherapy for...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000165453.HKD","HK0000306701.USD","02696","HK0000320223.HKD","HK0000320264.USD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2604937501","title":"Shanghai Henlius Biotech Inc - Nmpa Approves Ind Application for Phase 1B/2 Hlx701 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2604937501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604937501?lang=en_us&edition=fundamental","pubTime":"2026-01-20 16:58","pubTimestamp":1768899534,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YK0OD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02696","HK0000306685.HKD","HK0000165453.HKD","HK0000320223.HKD","BK1161","HK0000320264.USD","HK0000306701.USD"],"gpt_icon":0},{"id":"2604193766","title":"Shanghai Henlius Biotech Receives NMPA Approval for HLX701 Phase 1b/2 Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2604193766","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604193766?lang=en_us&edition=fundamental","pubTime":"2026-01-20 16:58","pubTimestamp":1768899512,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that the investigational new drug  application for a phase 1b/2 clinical trial of HLX701, a recombinant human SIRPα-IgG4 Fc fusion protein injection, in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer, has been approved by the National Medical Products Administration. As of the date of the announcement, no SIRPα-Fc fusion protein targeting CD47 has been approved for marketing globally. The company noted that successful development and commercialization of HLX701 cannot be guaranteed and advised shareholders and potential investors to exercise caution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL5w1DjB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","HK0000320264.USD","00656","HK0000306701.USD","HK0000306685.HKD","HK0000165453.HKD","BK1161","02696","BK1230"],"gpt_icon":0},{"id":"1147813290","title":"Shanghai Henlius (2696) Announces Approval for H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1147813290","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147813290?lang=en_us&edition=fundamental","pubTime":"2026-01-19 22:41","pubTimestamp":1768833679,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (Stock code: 2696) has received listing approval from The Stock Exchange of Hong Kong Limited on 19 January 2026 for the full circulation of 182,645,856 unlisted...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"1112130698","title":"Henlius (02696) Receives HKEX Approval for H-Share Full Circulation Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=1112130698","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112130698?lang=en_us&edition=fundamental","pubTime":"2026-01-19 22:36","pubTimestamp":1768833373,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that the company has obtained approval from The Stock Exchange of Hong Kong Limited, dated January 19, 2026, for the listing and trading of 182,645,856 H-shares, which...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","HK0000306701.USD","HK0000306685.HKD","02696","HK0000165453.HKD","HK0000320223.HKD","BK1161"],"gpt_icon":0},{"id":"2604904120","title":"Henlius Biotech Receives CSRC Filing Notice for H-Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2604904120","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604904120?lang=en_us&edition=fundamental","pubTime":"2026-01-19 12:02","pubTimestamp":1768795372,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech  has received a filing notice from the China Securities Regulatory Commission for its proposed H-share full circulation, according to a Friday Hong Kong bourse filing.Shares of the biotech firm were down nearly 2% in Monday morning trade.The filing covers the conversion and listing of 182.6 million domestic unlisted shares held by certain shareholders, the company said.The CSRC filing marks the completion of the regulatory filing process for the full-circulation plan.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000320264.USD","HK0000306701.USD","HK0000306685.HKD","02696","HK0000165453.HKD","HK0000320223.HKD","BK1161"],"gpt_icon":0},{"id":"1166255435","title":"HENLIUS Receives Filing Notice from China Securities Regulatory Commission for H-Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1166255435","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166255435?lang=en_us&edition=fundamental","pubTime":"2026-01-18 17:11","pubTimestamp":1768727495,"startTime":"0","endTime":"0","summary":"HENLIUS (Stock Code: 02696) has announced that the company recently received the \"Filing Notice for the 'Full Circulation' of Domestic Non-listed Shares of Shanghai Henlius Biotech, Inc.\" issued by...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","02696","HK0000306685.HKD","BK1161","HK0000320264.USD","HK0000306701.USD","HK0000320223.HKD"],"gpt_icon":0},{"id":"2604274639","title":"A Look At Shanghai Henlius Biotech (SEHK:2696) Valuation After FDA Acceptance Of HANBEITAI Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2604274639","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604274639?lang=en_us&edition=fundamental","pubTime":"2026-01-18 08:29","pubTimestamp":1768696194,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (SEHK:2696) is back in focus after the US FDA accepted its biologics license application for HANBEITAI, covering multiple oncology indications across colorectal, lung, brain, kidney, ovarian and cervical cancers.\nSee our latest analysis for Shanghai Henlius Biotech.\nThe HANBEITAI filing comes after a period of strong market interest, with a 30 day share price return of 12.72%, year to date share price return of 16.47%, and a very large 1 year total shareholder return...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/a-look-at-shanghai-henlius-biotech-sehk2696-valuation-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/a-look-at-shanghai-henlius-biotech-sehk2696-valuation-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HK0000320264.USD","HK0000306701.USD","02696","HK0000165453.HKD","DCF","HK0000306685.HKD","BK1161","HK0000320223.HKD"],"gpt_icon":0},{"id":"2603995008","title":"Shanghai Henlius Biotech Unveils \"Globalisation 2.0\" Strategy With Plans to Launch Over 20 Products Globally by 2030, Expand Innovation Pipeline, and Strengthen International Commercialisation Capabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2603995008","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603995008?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:00","pubTimestamp":1768568442,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Unveils \"Globalisation 2.0\" Strategy With Plans to Launch Over 20 Products Globally by 2030, Expand Innovation Pipeline, and Strengthen International Commercialisation Capabilities. Shanghai Henlius Biotech Inc. has announced its \"Globalisation 2.0\" strategy and mid-to-long-term innovation blueprint, outlining plans to expand its global biopharmaceutical footprint by 2030. The company aims to launch more than 20 products worldwide, including over 15 in the U.S. and European markets. Henlius intends to advance innovative therapeutic modalities such as antibody-drug conjugates , multi-specific antibodies, and T-cell engagers , targeting areas including oncology, autoimmune, metabolic, and central nervous system diseases. The company plans to further strengthen its global commercialisation capabilities and expects continued growth in international market revenue, reinforcing its position in the global biopharmaceutical industry.Disclaimer: This news brief was crea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLb2pqf0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","BK1230","HK0000165453.HKD","HK0000320223.HKD","HK0000320264.USD","00656","HK0000306685.HKD","BK1161","HK0000306701.USD"],"gpt_icon":0},{"id":"1104615862","title":"HENLIUS (02696): China Securities Regulatory Commission Issues Filing Notice for H-share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1104615862","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104615862?lang=en_us&edition=fundamental","pubTime":"2026-01-16 16:47","pubTimestamp":1768553258,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that the company has recently received the \"Filing Notice for the Full Circulation of Domestic Non-Listed Shares of Shanghai Henlius Biotech, Inc.\" issued by the China...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696","HK0000165453.HKD","HK0000306701.USD","HK0000320264.USD","HK0000320223.HKD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2603965122","title":"Shanghai Henlius Biotech Receives CSRC Approval for H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603965122","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603965122?lang=en_us&edition=fundamental","pubTime":"2026-01-16 16:30","pubTimestamp":1768552239,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that it has received the Notification of Filing on the \"Full Circulation\" of Domestic Unlisted Shares from the China Securities Regulatory Commission . This regulatory approval allows for the implementation of H Share Full Circulation for an aggregate of 182,645,856 unlisted shares held by certain shareholders of the company. The filing process with the CSRC has been completed, enabling these shares to be converted and listed as H shares on the Hong Kong Stock Exchange. If the conversion and listing are not completed within 12 months from the date of the filing notice, the company will be required to submit an updated filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL5ZVbNT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000306701.USD","HK0000165453.HKD","HK0000320264.USD","HK0000306685.HKD","HK0000320223.HKD","00656","BK1161","BK1230"],"gpt_icon":0},{"id":"1183034621","title":"Henlius (02696): Biologics License Application for Hanbeitai® (Bevacizumab Injection) Accepted by U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1183034621","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183034621?lang=en_us&edition=fundamental","pubTime":"2026-01-13 16:54","pubTimestamp":1768294463,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that the Biologics License Application (BLA) for its self-developed Hanbeitai® (Bevacizumab Injection) has been accepted for review by the U.S. Food and Drug Administration...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000306685.HKD","BK1161","HK0000306701.USD","HK0000320264.USD","HK0000320223.HKD","HK0000165453.HKD"],"gpt_icon":0},{"id":"2603501954","title":"FDA Accepts Biologics License Application for Henlius Hanbeitai Bevacizumab Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2603501954","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603501954?lang=en_us&edition=fundamental","pubTime":"2026-01-13 16:52","pubTimestamp":1768294352,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that its Biologics License Application  for HANBEITAI  has been accepted by the United States Food and Drug Administration . The application covers multiple proposed indications, including metastatic colorectal cancer, unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel for first-line treatment, recurrent glioblastoma in adults, metastatic renal cell carcinoma in combination with interferon alfa, epithelial ovarian, fallopian tube cancer or primary peritoneal cancer, and persistent, recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotecan. The BLA submission is based on data demonstrating high similarity and no clinically meaningful differences between HANBEITAI and its reference drug.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL2S0bbS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000320223.HKD","02696","BK1230","HK0000165453.HKD","HK0000306685.HKD","HK0000320264.USD","00656","HK0000306701.USD"],"gpt_icon":0},{"id":"2603019375","title":"Shanghai Henlius Biotech Inc - Biologics License Application for Hanbeitai (Bevacizumab Injection) Accepted by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2603019375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603019375?lang=en_us&edition=fundamental","pubTime":"2026-01-13 16:52","pubTimestamp":1768294343,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YD1OJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02696","HK0000320264.USD","BK1161","HK0000306685.HKD","HK0000320223.HKD","HK0000306701.USD","HK0000165453.HKD"],"gpt_icon":0},{"id":"1146080787","title":"Hong Kong Stock Movement | HENLIUS (02696) Surges Over 8% Again, Broad-Spectrum Anti-Tumor PD-L1 ADC HLX43 Phase II Data for End-Line Esophageal Squamous Cell Carcinoma First Released","url":"https://stock-news.laohu8.com/highlight/detail?id=1146080787","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146080787?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:16","pubTimestamp":1768270598,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) surged over 8% again, with an increase of 8.05% at the time of writing, reaching HK$69.8, and a turnover of HK$18.6408 million. On January 9th, at the 2026 American Society of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4023","ADC","HK0000165453.HKD","PD","HK0000320223.HKD","BK4080","LU1169590202.USD","HK0000320264.USD","BK4231","LU1169589451.USD","HK0000306685.HKD","02696","HK0000306701.USD"],"gpt_icon":0},{"id":"1118913475","title":"HENLIUS (02696) Surges Over 5% Intraday as Company Unveils First Phase II Clinical Data for PD-L1 ADC in Esophageal Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1118913475","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118913475?lang=en_us&edition=fundamental","pubTime":"2026-01-08 11:24","pubTimestamp":1767842659,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.39%, trading at HKD 66.65, with a turnover of HKD 23.9053 million. On the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","BK1161","BK4023","BK4080","HK0000165453.HKD","BK4231","LU1169589451.USD","LU1169590202.USD","02696","ADC"],"gpt_icon":0},{"id":"2601740382","title":"Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation After HLX37 Enters Phase 1 Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601740382","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601740382?lang=en_us&edition=fundamental","pubTime":"2026-01-08 01:46","pubTimestamp":1767807982,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (SEHK:2696) has dosed the first patient in its phase 1 trial of HLX37, a bispecific antibody that targets PD-L1 and VEGF in advanced or metastatic solid tumours in Mainland China.\nSee our latest analysis for Shanghai Henlius Biotech.\nThe HLX37 trial update comes after a mixed stretch for the stock, with a 1-day share price return of 2.00% and a 7-day share price return of 11.92% but a 90-day share price return of 15.71%. However, the 1-year total shareholder return of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","DCF","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"1165136813","title":"HENLIUS (02696.HK) Surges Nearly 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165136813","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165136813?lang=en_us&edition=fundamental","pubTime":"2026-01-05 11:30","pubTimestamp":1767583835,"startTime":"0","endTime":"0","summary":"HENLIUS (02696.HK) is currently up nearly 9%, having gained 8.62% to reach HKD 63.65 at the time of writing, with a trading volume of HKD 29.04 million.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"1178651656","title":"Hong Kong Stock Movement | HENLIUS (02696) Surges Nearly 9% as IND Applications for Three Innovative Solid Tumor Drugs Are Accepted Concurrently","url":"https://stock-news.laohu8.com/highlight/detail?id=1178651656","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178651656?lang=en_us&edition=fundamental","pubTime":"2026-01-05 11:06","pubTimestamp":1767582385,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) is currently up nearly 9%. As of the time of writing, the stock has risen 8.62% to HK$63.65, with a turnover of HK$29.04 million. On December 30, HENLIUS announced that the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","159992","IND","BK1574","06978","BK1161","02696"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0796},{"period":"1month","weight":0.0249},{"period":"3month","weight":-0.1114},{"period":"6month","weight":-0.0064},{"period":"1year","weight":2.4592},{"period":"ytd","weight":0.0841}],"compareEarnings":[{"period":"1week","weight":-0.0154},{"period":"1month","weight":0.0304},{"period":"3month","weight":0.0238},{"period":"6month","weight":0.0471},{"period":"1year","weight":0.3222},{"period":"ytd","weight":0.0372}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Henlius Biotech Inc is a China-based company principally engaged in biopharmaceutical research and development, biopharmaceutical services and biopharmaceutical production and sales. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The Company mainly operates its businesses in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.033},{"month":2,"riseRate":0.666667,"avgChangeRate":0.108951},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016995},{"month":4,"riseRate":0.833333,"avgChangeRate":0.128587},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"HENLIUS","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HENLIUS,02696,HENLIUS股票,HENLIUS股票老虎,HENLIUS股票老虎国际,HENLIUS行情,HENLIUS股票行情,HENLIUS股价,HENLIUS股市,HENLIUS股票价格,HENLIUS股票交易,HENLIUS股票购买,HENLIUS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}